Proposed risk factors include a change in bile acid production and secretion, suppressed cholecystokinin secretion, decreased emptying time, prolonged gallbladder refilling, and weight loss
They mean that the metabolic and behavioral changes associated with tirzepatide treatment can, in some circumstances, create environments where UTIs are more likely if preventive measures are not taken
Newer dual-hormone drugs like tirzepatide have since pushed the averages higher, toward 20%
Loren Pickart, 7% GHK-CU ACCELERANT- Extra Strength Booster
Yet with preclinical trials ongoing, the list of insurance-approved uses could soon expand to include sleep apnea (which can be weight-related), Parkinsons, dementia, and more